- Home
- PRKS vs NAMS Comparison
PRKS vs NAMS Comparison
Compare PRKS & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRKS
- NAMS
- Stock Information
- Founded
- PRKS 1959
- NAMS 2019
- Country
- PRKS United States
- NAMS Netherlands
- Employees
- PRKS N/A
- NAMS N/A
- Industry
- PRKS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- PRKS Health Care
- NAMS Health Care
- Exchange
- PRKS Nasdaq
- NAMS Nasdaq
- Market Cap
- PRKS 2.8B
- NAMS 2.5B
- IPO Year
- PRKS 2013
- NAMS N/A
- Fundamental
- Price
- PRKS $46.63
- NAMS $21.28
- Analyst Decision
- PRKS Buy
- NAMS Strong Buy
- Analyst Count
- PRKS 13
- NAMS 9
- Target Price
- PRKS $57.38
- NAMS $41.11
- AVG Volume (30 Days)
- PRKS 686.7K
- NAMS 804.3K
- Earning Date
- PRKS 08-07-2025
- NAMS 08-11-2025
- Dividend Yield
- PRKS N/A
- NAMS N/A
- EPS Growth
- PRKS 3.53
- NAMS N/A
- EPS
- PRKS 3.85
- NAMS N/A
- Revenue
- PRKS $1,714,827,000.00
- NAMS $47,140,000.00
- Revenue This Year
- PRKS $2.13
- NAMS N/A
- Revenue Next Year
- PRKS $2.33
- NAMS $73.09
- P/E Ratio
- PRKS $12.11
- NAMS N/A
- Revenue Growth
- PRKS N/A
- NAMS 586.97
- 52 Week Low
- PRKS $37.68
- NAMS $14.06
- 52 Week High
- PRKS $60.83
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- PRKS 43.17
- NAMS 48.31
- Support Level
- PRKS $45.74
- NAMS $21.55
- Resistance Level
- PRKS $54.13
- NAMS $24.18
- Average True Range (ATR)
- PRKS 1.58
- NAMS 1.22
- MACD
- PRKS -0.42
- NAMS -0.20
- Stochastic Oscillator
- PRKS 11.71
- NAMS 17.50
About PRKS United Parks & Resorts Inc. Common Stock
United Parks & Resorts Inc is an American theme park and entertainment company. Its core business is the operation of theme parks and entertainment facilities involving sea animals across the country under prominent brands such as SeaWorld, Busch Gardens, Aquatica, Discovery Cove, and Sesame Place. The company generates the majority of its revenue from selling admission tickets for its theme parks.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.